Showing 3791-3800 of 4164 results for "".
- Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-screened-in-the-whistler-phase-3b-trial-of-ncx-470-in-glaucoma/2482018/Nicox announced that the first patient has been screened in the Whistler phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in IOP lowering. NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, is the company's le
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- Ocugen Announces First Patient Dosed in Phase 1/2 Trial of OCU410 Modifier Gene Therapy for GAhttps://modernod.com/news/ocugen-announces-first-patient-dosed-in-phase-12-trial-of-ocu410-modifier-gene-therapy-for-ga/2482006/Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for dry AMD (AMD). This phase 1/2 trial will assess the safety and efficacy of OCU410 for geographic at
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- Skye Bioscience Begins Phase 2 Study of SBI-100 Ophthalmic Emulsion to Treat Glaucomahttps://modernod.com/news/skye-bioscience-begins-phase-2-study-of-sbi-100-ophthalmic-emulsion-to-treat-glaucoma/2481984/Skye Bioscience, which is developing drugs targeting the endocannabinoid system and focusing on glaucoma and metabolic conditions, announced it has treated the first patient in its phase 2 clinical trial evaluating SBI-100 ophthalmic emulsion’s ability to lower IOP as well as safe
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- EyeBio Announces Expansion of Series A to $130 Million to Advance Development of Restoret for Retinal Diseaseshttps://modernod.com/news/eyebio-announces-expansion-of-series-a-to-130-million-to-advance-development-of-restoret-for-retinal-diseases/2481969/Eyebiotech announced the successful close of an extension to its Series A financing, bringing the total raised to date to $130 million. EyeBio will use the proceeds from the funding to accelerate the company’s clinical development program and further build out its retina pipeline.
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- GATHER2 Study Shows Izervay Monthly or Every Other Month Reduced GA Lesion Growth Through 2 Yearshttps://modernod.com/news/gather2-study-shows-izervay-monthly-or-every-other-month-reduced-ga-lesion-growth-through-2-years/2481944/Astellas Pharma announced results from the GATHER2 phase 3 clinical trial, demonstrating Izervay (avacincaptad pegol intravitreal solution) continued to reduce the rate of geographic atrophy (GA) lesion growth for both every month (EM) and every-other-month (EOM) dosing vs. sham through
- Verana Health Partners with Foundation Fighting Blindness to Integrate Genetic Testing Data into Real-World Evidence Researchhttps://modernod.com/news/verana-health-partners-with-foundation-fighting-blindness-to-integrate-genetic-testing-data-into-real-world-evidence-research/2481940/Verana Health and the Foundation Fighting Blindness announced a partnership focused on providing the life sciences community with deeper and broader data to optimize and expedite clinical trials. Under the partnership, the Foundation will provide Verana with de-identified genomics